Dapaz en es it fr

Dapaz Brand names, Dapaz Analogs

Dapaz Brand Names Mixture

  • No information avaliable

Dapaz Chemical_Formula

C20H23NS

Dapaz RX_link

No information avaliable

Dapaz fda sheet

Dapaz msds (material safety sheet)

Dapaz Synthesis Reference

No information avaliable

Dapaz Molecular Weight

309.469 g/mol

Dapaz Melting Point

< 25 oC

Dapaz H2O Solubility

Soluble as HCl salt

Dapaz State

Liquid

Dapaz LogP

5.7

Dapaz Dosage Forms

Tablets (oral, 1 mg)

Dapaz Indication

Used for the symptomatic treatment of parkinsonism.

Dapaz Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

Dapaz Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

Dapaz side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

Dapaz Patient Information

Dapaz Organisms Affected

Humans and other mammals